Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - xromi
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp4ee3eaba97a2c229abd66d955627a070
identifier: http://ema.europa.eu/identifier
/EU/1/19/1366/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Xromi 100 mg/ml oral solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-4ee3eaba97a2c229abd66d955627a070
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/19/1366/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - xromi
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Xromi contains hydroxycarbamide, a substance which reduces the growth and multiplication of some cells in the bone marrow. These effects lead to a reduction of circulating red, white and coagulation blood cells. In Sickle Cell Disease, hydroxycarbamide also helps to prevent red blood cells from taking the abnormal sickle shape. Sickle Cell disease is an inherited blood disorder that affects the disc shaped red cells of the blood. Some cells become abnormal, rigid and take a crescent or sickle shape which leads to anaemia. The sickle cells also get stuck in blood vessels, blocking blood flow. This can cause acute pain crises and organ damage.
Xromi is used to prevent the complications of blocked blood vessels caused by Sickle Cell Disease in patients over 2 years of age. Xromi will decrease the number of painful crises as well as the need for hospitalisation as a result of the disease.
Do not take Xromi
Warnings and precautions
Test and checks
Your doctor will run blood tests:
Talk to your doctor, pharmacist or nurse before taking Xromi
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Xromi.
Skin cancer has been reported in patients receiving long term hydroxycarbamide. You should protect your skin from the sun and regularly inspect your skin yourself during the treatment and after discontinuation of the therapy with hydroxycarbamide. Your doctor will also inspect your skin during routine follow-up visits.
Children
Do not give this medicine to children from birth to 2 years of age because it is unlikely to be safe.
Other medicines and Xromi
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor, nurse or pharmacist if you are taking any of the following:
Pregnancy, breast-feeding and fertility
Do not take Xromi if you are planning to have a baby without first speaking to your doctor for advice. This applies to both men and women. Xromi may harm your sperm or eggs.
Xromi must not be used during pregnancy. Xromi should be stopped 3 to 6 months prior to becoming pregnant, if possible.
Please contact your doctor immediately if you think you may be pregnant. The use of effective contraception is strongly recommended for both male and female patients.
For male patients taking Xromi, if your partner becomes pregnant or plans to become pregnant, your doctor will discuss with you the potential benefits and risks of continuing using Xromi.
Hydroxycarbamide, the active substance of Xromi, passes into human breast milk. Do not breastfeed while taking Xromi. Ask your doctor or pharmacist for advice.
Driving and using machines
Xromi can make you feel drowsy. You should not drive or operate any machinery unless it has been shown not to affect you and you have discussed it with your doctor.
Xromi contains methyl parahydroxybenzoate (E218)
Xromi contains methyl parahydroxybenzoate (E218) which may cause allergic reactions (possibly delayed).
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Xromi should only be given to you by a specialist doctor who is experienced in treating blood problems.
Check with your doctor or pharmacist if you are not sure. The usual starting dose for adults, adolescents and children over the age of 2 years is 15 mg/kg each day and the usual maintenance dose is between 20-25 mg/kg. Your doctor will prescribe the correct dose for you. Sometimes the doctor may change your dose of Xromi, for example as a result of different tests. If you are not sure how much medicine to take, always ask your doctor or nurse.
Xromi with food and drink You can take this medicine with or after meals at any time of the day. However, the choice of method and time of day should be consistent from day to day.
Use in elderly You may be more sensitive to the effects of Xromi and your doctor may need to give you a lower dose.
If you have kidney disease Your doctor may need to give you a lower dose. You should not take Xromi if you have severe kidney disease.
Handling Your pack of Xromi contains a bottle of medicine, a cap, a bottle adaptor and two dosing syringes (a 3 ml and a 10 ml syringe). Always use the syringes provided to take your medicine.
It is important that you use the correct dosing syringe for your medicine. Your doctor or pharmacist will advise which syringe to use depending on the dose that has been prescribed.
The smaller 3 ml syringe, marked from 0.5 ml to 3 ml, is for measuring doses of less than or equal to 3 ml. You should use this one if the total amount you have to take is less than or equal to 3 ml (each graduation of 0.1 ml contains 10 mg of hydroxycarbamide). The larger 10 ml syringe, marked from 1 ml to 10 ml, is for measuring doses of more than 3 ml. You should use this one if the total amount you have to take is more than 3 ml (each graduation of 0.5 ml contains 50 mg of hydroxycarbamide).
If you are a parent or care giver administering the medicine, wash your hands before and after administering a dose. Wipe up spillages immediately. To decrease the risk of exposure disposable gloves should be used when handling Xromi. To minimise air bubbles, do not shake the bottle before administering a dose.
If Xromi comes into contact with skin, eyes or nose, it should be washed immediately and thoroughly with soap and water.
When you use the medicine follow the instructions below:
Repeat the above for each dose as instructed by your doctor or pharmacist.
If you take more Xromi than you should
If you take more Xromi than you should, tell your doctor or go to a hospital immediately. Take the medicine pack and this leaflet with you. The most common symptoms of overdose with Xromi are:
If you forget to take Xromi
Tell your doctor. Do not take a double dose to make up for a forgotten dose.
If you stop taking Xromi
Do not stop taking your medicine unless advised by your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any of the following side effects, talk to your doctor or go to hospital immediately:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1000 people
Very rare: may affect up to 1 in 10,000 people
Other side effects which are not mentioned above are listed below. Speak to your doctor if you are concerned by any of these side effects.
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Other side effects (the frequency is unknown)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Xromi contains
The active substance is hydroxycarbamide. One ml of solution contains 100 mg of hydroxycarbamide.
The other ingredients are xanthan gum, sucralose (E955), strawberry flavour, methyl parahydroxybenzoate (E218), sodium hydroxide, and purified water. See section 2 Xromi contains methyl parahydroxybenzoate .
What Xromi looks like and contents of the pack
Xromi is a clear, colourless to pale yellow, oral solution. It comes in glass bottles of 150 ml capped with a child-resistant closure. Each pack contains one bottle, a bottle adaptor and two dosing syringes (a syringe graduated to 3 ml and a syringe graduated to 10 ml). Your doctor or pharmacist will advise which syringe to use depending on the dose that has been prescribed
Marketing Authorisation Holder Nova Laboratories Ireland Limited 3rd Floor Ulysses House Foley Street, Dublin 1 D01 W2T2 Ireland
Manufacturer Pronav Clinical Ltd.
Unit 5
Dublin Road Business Park
Carraroe, Sligo
F91 DIreland
This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-4ee3eaba97a2c229abd66d955627a070
Resource Composition:
Generated Narrative: Composition composition-en-4ee3eaba97a2c229abd66d955627a070
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1366/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - xromi
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp4ee3eaba97a2c229abd66d955627a070
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp4ee3eaba97a2c229abd66d955627a070
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1366/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Xromi 100 mg/ml oral solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en